J Korean Ophthalmol Soc.  2013 Jan;54(1):38-45. 10.3341/jkos.2013.54.1.38.

Antibiotics Susceptibility in Bacterial Keratitis and Proper Initial Treatment

• Yoon JH
• Jung JW
• Moon HS
• Moon HS
• Shyn KH
• Kim KH

• KMID: 2216447
• DOI: http://doi.org/10.3341/jkos.2013.54.1.38

Abstract

PURPOSE
The present study aims to determine the common pathogens involved in the etiology of bacterial keratitis and to analyze not only the antibiotic susceptibility of bacterial isolates from patients with bacterial keratitis but also the propriety of initial treatment.
METHODS
A retrospective study of 161 eyes in 161 patients with bacterial keratitis, who were diagnosed by cultures from 2000 to 2011, was performed. Causative bacteria and antibiotic susceptibility were evaluated in consecutive 6-year periods.
RESULTS
The most common bacteria was the pseudomonas species in the 2 time periods tested and cefazolin with tobramycin was the most commonly used antibiotic (125 cases, 77.6%) for initial treatment of bacterial keratitis. In vitro testing showed gram-negative susceptibility to tobramycin and ciprofloxacin was over 70%, gram-positive susceptibility to cephalothin and vancomycin was 100% and there was no significant difference between the 2 time periods tested. Eight cases had resistance to the initial treatment, but only 1 case showed treatment failure.
CONCLUSIONS
Antibiotics used for initial treatment of bacterial keratitis were able to obtain a proper effect but several cases showed bacterial resistance to antibiotics. Thus, continued testing is essential to monitor for antibiotic resistance.

Keyword

Antibiotics; Antibiotic susceptibility; Bacterial keratitis; Resistance

MeSH Terms

Anti-Bacterial Agents*
Bacteria
Cefazolin
Cephalothin
Ciprofloxacin
Drug Resistance, Microbial
Humans
Keratitis*
Pseudomonas
Retrospective Studies
Tobramycin
Treatment Failure
Vancomycin
Anti-Bacterial Agents
Cefazolin
Cephalothin
Ciprofloxacin
Tobramycin
Vancomycin

Reference

References

1. Verhelst D, Koppen C, Van Looveren J, et al. Clinical, abdominal and cost aspects of contact lens related infectious keratitis in Belgium: results of a seven-year retrospective study. Bull Soc Belge Ophthalmol. 2005; 297:7–15.

2. Ibrahim YW, Boase DL, Cree IA. Factors affecting the abdominal of Acanthamoeba keratitis. Ophthalmic Epidemiol. 2007; 14:53–60.

3. Forster RK. Conrad Berens Lecture. The management of infectious keratitis as we approach the 21st century. CLAO J. 1998; 24:175–80.

4. Scott IU, Flynn HW Jr, Feuer W, et al. Endophthalmitis associated with microbial keratitis. Ophthalmology. 1996; 103:1864–70.

5. Krachmer JH, Mannis MJ, Holland EJ. Cornea. 2nd ed.Philadelphia: Elsevier Mosby, v. 1.;2005. p. 1021–3.

6. Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Ophthalmology. 1999; 106:80–5.

7. Schmitz FJ, Verhoef J, Fluit AC. Prevalence of aminoglycoside abdominal in 20 European university hospitals participating in the European SENTRY Antimicrobial Surveillance Programme. Eur J Clin Microbiol Infect Dis. 1999; 18:414–21.

8. Baum JL. Initial therapy of suspected microbial corneal ulcers. I. Broad antibiotic therapy based on prevalence of organisms. Surv Ophthalmol. 1979; 24:97–105.

9. Cokingtin CD, Hyndiuk RA. Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections. Am J Ophthalmol. 1991; 112:25S–8S.

10. Jones DB. Initial therapy of suspected microbial corneal ulcers. II. Specific antibiotic therapy based on corneal smears. Surv Ophthalmol. 1979; 24:97. 105–16.

11. Kowalski RP, Karenchak LM, Gordon YJ. Comparison of abdominal and ofloxacin using human corneal susceptibility levels. Cornea. 1998; 17:282–7.

12. Leibowitz HM. Corneal disorders: clinical diagnosis and abdominal. 1st ed.Philadelphia: Saunders;1984. p. 353–86.

13. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol. 1991; 112:34S–47S.

14. Afshari NA, Ma JJ, Duncan SM, et al. Trends in resistance to abdominal, cefazolin, and gentamicin in the treatment of bacterial keratitis. J Ocul Pharmacol Ther. 2008; 24:217–23.

15. Yeh DL, Stinnett SS, Afshari NA. Analysis of bacterial cultures in infectious keratitis, 1997 to 2004. Am J Ophthalmol. 2006; 142:1066–8.

16. Fong CF, Hu FR, Tseng CH, et al. Antibiotic susceptibility of abdominal isolates from bacterial keratitis cases in a university hospital in Taiwan. Am J Ophthalmol. 2007; 144:682–9.

17. Hahn YH, Lee SJ, Hahn TW, et al. Antibiotic susceptibilities of abdominal isolates from patients with bacterial keratitis: a abdominal study. J Korean Ophthalmol Soc. 1999; 40:2401–10.

18. Kim WJ, Kweon EY, Lee DW, et al. Prognostic factor and abdominal susceptibility in bacterial keratitis: results of an eight-year period. J Korean Ophthalmol Soc. 2009; 50:1495–504.

19. Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol. 1996; 121:712–5.

20. Jhanji V, Sharma N, Satpathy G, Titiyal J. Fourth-generation fluo-roquinolone-resistant bacterial keratitis. J Cataract Refract Surg. 2007; 33:1488–9.

21. Moshirfar M, Mirzaian G, Feiz V, Kang PC. Fourth-generation flu-oroquinolone-resistant bacterial keratitis after refractive surgery. J Cataract Refract Surg. 2006; 32:515–8.

22. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000; 107:1497–502.

23. Smitha S, Lalitha P, Prajna VN, Srinivasan M. Susceptibility trends of pseudomonas species from corneal ulcers. Indian J Med Microbiol. 2005; 23:168–71.

24. Denton M, Kerr KG. Microbiological and clinical aspects of abdominal associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998; 11:57–80.

25. Penland RL, Wilhelmus KR. Stenotrophomonas maltophilia ocular infections. Arch Ophthalmol. 1996; 114:433–6.

26. Bottone EJ, Madayag RM, Qureshi MN. Acanthamoeba keratitis: synergy between amebic and bacterial cocontaminants in contact lens care systems as a prelude to infection. J Clin Microbiol. 1992; 30:2447–50.

27. Mett H, Rosta S, Schacher B, Frei R. Outer membrane permeability and beta-lactamase content in Pseudomonas maltophilia clinical isolates and laboratory mutants. Rev Infect Dis. 1988; 10:765–9.

28. Vartivarian S, Anaissie E, Bodey G, et al. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother. 1994; 38:624–7.

29. Snyder ME, Katz HR. Ciprofloxacin-resistant bacterial keratitis. Am J Ophthalmol. 1992; 114:336–8.

30. Kim EK, Kim HB, Kim SY. Comparative bioavailability and efficasy of tobra(R) or tobrex(R). J Korean Ophthalmol Soc. 1989; 30:175–80.

31. Kowal VO, Levey SB, Laibson PR, et al. Use of routine antibiotic sensitivity testing for the management of corneal ulcers. Arch Ophthalmol. 1997; 115:462–5.